  Rheumatoid arthritis (RA) is a chronic, disabling and incurable autoimmune
disease. It has been widely recognized that gut microbial dysbiosis is an
important contributor to the pathogenesis of RA, although distinct alterations
in microbiota have been associated with this disease. Yet, the metabolites that
mediate the impacts of the gut microbiome on RA are less well understood. Here,
with microbial profiling and non-targeted metabolomics, we revealed profound
yet diverse perturbation of the gut microbiome and metabolome in RA patients in
a discovery set. In the Bacteroides-dominated RA patients, differentiation of
gut microbiome resulted in distinct bile acid profiles compared to healthy
subjects. Predominated Bacteroides species expressing BSH and 7a-HSDH
increased, leading to elevated secondary bile acid production in this subgroup
of RA patients. Reduced serum fibroblast growth factor-19 and dysregulated bile
acids were evidence of impaired farnesoid X receptor-mediated signaling in the
patients. This gut microbiota-bile acid axis was correlated to ACPA. The
patients from the validation sets demonstrated that ACPA-positive patients have
more abundant bacteria expressing BSH and 7a-HSDH but less Clostridium scindens
expressing 7a-dehydroxylation enzymes, together with dysregulated microbial
bile acid metabolism and more severe bone erosion than ACPA-negative ones.
Mediation analyses revealed putative causal relationships between the gut
microbiome, bile acids, and ACPA-positive RA, supporting a potential causal
effect of Bacteroides species in increasing levels of ACPA and bone erosion
mediated via disturbing bile acid metabolism. These results provide insights
into the role of gut dysbiosis in RA in a manifestation-specific manner, as
well as the functions of bile acids in this gut-joint axis, which may be a
potential intervention target for precisely controlling RA conditions.
